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Abstract 
Response Assessment in Neuro-Oncology - Patient Reported Outcome (RANO-PRO) working group is 
an international multidisciplinary collaborative initiative with the aim to provide guidance on the use 
of PRO measures in clinical trials and practice for adult brain tumour patients. Findings of PROs and 
other patient-centred outcome measures are essential to inform the research community, policy 
makers, physicians and patients in treatment decision-making, in conjunction with traditional 
outcome measures such as survival and clinical/radiological response. However, to be of value, PROs 
should be well-defined and reliable in order to generate high-quality evidence. This requires not only 
proper collection, analysis, interpretation and reporting of PRO data, but also the application of 
appropriate PRO instruments, specifically with respect to the content and measurement properties. 
Previous initiatives in oncology have focused on guidelines concerning the collection, analysis, 
interpretation and reporting of PRO data. Our recommendations on the use of specific PRO 
measures (i.e. research question, content validity and other measurement properties) in brain 
tumour research may additionally help to improve the quality of PRO evidence derived from neuro-
oncological studies, and may add a new dimension to how the value of therapeutics is assessed in 
brain tumour patients. Here we present the RANO-PRO working plan.  
4 
 
Role of patient-reported outcomes (PROs) in oncology 
The goal of all therapeutics is to improve life for people suffering from disease. The traditional 
metric used in oncology to demonstrate this goal in therapeutic studies is prolonged survival or its 
surrogate, prolonged time to disease progression. However, the patient and regulatory community 
have increasingly emphasized the need to demonstrate that a therapy improves the patient function 
and health-related quality of life (HRQoL). Patient Reported Outcomes (PROs) are important tools for 
quantifying symptoms, function or HRQoL. The US Food and Drug Administration (FDA) and the 
European Medicines Agency (EMA) have defined a PRO as a measurement that is directly reported 
by patients1,2, and reflects the patients’ perception of a disease and its treatment.2 A PRO can be 
measured either through self-report or interview, given that the interviewer only reports the 
responses of the patient. PRO measures may cover symptoms, functioning and health-related quality 
of life (HRQoL), but also topics such as adherence to treatment or satisfaction with care. PROs are 
distinctive from other types of patient-centred outcome measures, because they can capture 
concepts that are only known to the patient, such as nausea, fatigue or pain severity, but also 
mental health aspects including distress and future uncertainty.3 The FDA has defined four types of 
patient-centred outcome measures, collectively called Clinical Outcome Assessments (COAs)4, 
including PRO measures, clinician-reported outcome (ClinRO) measures, observer-reported outcome 
(ObsRO) measures and performance outcome (PerfO) measures (Table 1). Unlike PRO measures, 
ClinRO and ObsRO are measurements that are based on a report that comes from a health-care 
professional or someone other than the patient or the health-care professional (e.g. a relative), 
respectively. In some cases, the same concept, for example cognitive symptoms, can be measured 
with different COAs.  
 COAs can provide additional information about the beneficial and adverse effects of a new 
treatment strategy, adding context to information on radiological response assessed on computed 
tomography (CT) / magnetic resonance imaging (MRI), clinical response based on a physical 
examination, and progression-free or overall survival.6,7 In clinical trials, information from both 
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sources can be used to determine the net clinical benefit of a new treatment strategy, in which the 
impact of treatment on both outcomes should be weighed. This information can be used to inform 
regulatory agencies in their decision to approve an experimental drug for use beyond clinical trials.8,9 
In clinical practice, information from PROs can be used in shared decision-making, in which patients 
together with their primary caregiver and physician make a treatment decision using the best 
available evidence.10 Results of COAs assessed over time may also be used in clinical practice for 
needs assessment, and to monitor an individual patient’s symptoms or functioning during the 
disease trajectory.11 By monitoring treatment effects, opportunities for symptom management may 
be identified, as well as timely referral to another health care professional (e.g., referral to a 
neuropsychologist in case of cognitive difficulties) or trigger points for initiation of palliative care. 
Integration of PROs into routine clinical care was even found to be associated with improved 
survival.12 
 
Determinants of quality of PRO evidence 
Findings of PROs and other patient-centred outcomes are crucial to inform the research community, 
policy makers, and physicians and patients in treatment decision-making, in conjunction with 
traditional outcome measures such as survival and clinical and radiological response. Therefore, to 
be of value, PROs should be well-defined and reliable13 in order to generate high-quality evidence. 
The generation of high-quality evidence requires consideration of several aspects (Figure 1). One 
aspect is that the selection of a PRO for a clinical study should coincide with the research question. 
PROs can be used as primary, secondary or exploratory outcome measures. For example, the 
primary objective of a study could be to improve symptoms or functioning of patients, for which a 
PRO can be used, while PROs can also be used as secondary endpoint to support the clinical benefit 
in a trial in which survival is the primary endpoint, or lastly, PRO data can be used as supportive data 
to better describe the patients’ experience in clinical trials, including toxicity and tolerability 
assessments in dose finding studies. This requires the selection of an appropriate PRO measure, 
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reflecting the goal of the study. Moreover, it is important to measure the construct that is intended 
to be measured, for which different types of PROs can be used. For example, a specific symptom 
(e.g. fatigue, depression or anxiety) or multiple symptoms, functioning in daily life, or the perceived 
HRQoL. The design of the study is another important aspect, in particular with respect to the 
assessment schedule. If the objective of a study is to assess the immediate toxic effects of a 
treatment the timing of the measurements should be different from when the objective is to assess 
the impact of a treatment strategy on the longer term.14,15 An important consideration here is the 
time frame addressed for the selected PRO, e.g., covering the last week or the last month. Certain 
toxicities may not be captured if the time is too short or too long. The statistical analysis of PRO data 
is also an important aspect in generating reliable results.16 Different analytical approaches may lead 
to conflicting results. For example, results of a cross-sectional analysis may favour treatment B over 
A, while the longitudinal analysis may not favour one treatment over the other. Even when 
appropriate statistical methods have been applied, interpretation of the results is key in drawing 
conclusions. Looking at statistically significant differences only may result in a different conclusion 
when compared to looking at both statistically and clinically relevant differences. Another challenge 
in interpretation is when multiple outcomes are used that measure the same concept, but results 
are conflicting. A final important aspect that should be considered in the generation of high-quality 
PRO evidence is the level of reporting of the results. Key aspects of the used methodology, statistical 
approach, results (e.g., baseline scores, and a description of missing data) and interpretation (e.g. 
clinical significance and generalisability of results) should be reported adequately, to facilitate critical 
appraisal of study results17. 
 To enhance the generation of high-quality PRO evidence, several efforts in the field of 
oncology have been established, some of which are currently ongoing (Table 2). For example, 
Standard Protocol Items: Recommendation for Interventional Trials in Patient Reported Outcomes 
(SPIRIT-PRO) aims to provide guidance on what specific PRO protocol items should be included in 
trial protocols.18 The Setting International Standards in Analyzing Patient-Reported Outcomes and 
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Quality of Life Endpoints Data (SISAQOL) consortium aims to develop a guideline and best practices 
for standardising the analysis and interpretation of PRO outcomes in cancer clinical trials.16 
Recommendations for the standardisation of the level of PRO reporting were introduced by the 
International Society for Quality of Life Research (ISOQOL); CONsolidated Standards of Reporting 
Trials in Patient Reported Outcomes (CONSORT-PRO).19,20 These efforts will result in international 
standards for the collection, analysis, interpretation and reporting of PRO data, contributing to an 
enhanced quality of PRO evidence. Also, the FDA published  PRO Guidance for Industry, a framework 
describing optimal PRO development, trial design and analysis of PRO data, which can be specifically 
used to support oncology labelling claims.8 Although the COnsensus-based Standards for the 
selection of health Measurement INstruments (COSMIN) initiative developed standards for the 
evaluation of the methodological quality of studies on the measurement properties of health 
measurement instruments21, for many PRO measures this has not been investigated properly. 
However, if PRO findings should be of high quality, the tools should be appropriate as well, both in 
terms of content and measurement properties.  
 
Use of PRO in brain tumour patients 
Brain tumour patients are different from other cancer patients in that they have cancer that is 
directly impacting their neurological function, making their course of disease different. Although 
brain tumour patients also report general cancer-related symptoms such as fatigue, drowsiness and 
constipation, they also more frequently report disease-specific symptoms such as seizures, motor 
dysfunction, cognitive deficits, and symptoms caused by elevated intracranial pressure (e.g. 
headache).22-29 This means that general cancer PRO instruments may not be appropriate or sufficient 
for brain tumour patients, as they may not cover all relevant issues. 
Current standard treatment of brain tumours may comprise surgery, radiotherapy and/or 
chemotherapy, depending on the type and location of the tumour.30-37 New treatment opportunities 
are currently being explored and include targeted treatment and immunotherapy.38-42 Despite the 
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large variation in type and location of the tumour, treatments and prognosis, all brain tumour 
patients may suffer from impaired functioning. 
Because of the poor prognosis of patients with glioblastoma, primary central nervous system 
lymphoma (PCNSL) or brain metastases, brain tumours are a good example of a disease in which not 
only prolonged (progression-free) survival is important, but also maintenance or improvement of 
functioning during the entire disease trajectory. This resulted in an increased use of patient-centred 
outcomes in this field of research in the last decades. Although patients with low-grade glioma or 
meningioma may survive for many years, they may experience late effects (i.e. side effects that 
become apparent months or years after treatment has ended) caused by anti-tumour treatment 
(e.g. radiotherapy) and/or supportive treatment such as corticosteroids and anti-epileptic drugs. 
These late effects include for example fatigue, peripheral neuropathy, muscle weakness, cognitive 
dysfunction or radiation-induced secondary malignancies43-47, and may also impact the patients’ 
functioning in daily life. More recently there has been a shift towards focus on the evaluation of 
patient’s functioning in these long-term survivors.43,48  
Several PRO measures are available in neuro-oncology to measure the impact of the tumour 
and its treatment, both on the short- and long-term. These PRO measures may be one-dimensional 
(measuring one single aspect, e.g. symptoms of depression or anxiety) or multidimensional 
(measuring multiple aspects, e.g. HRQoL). Frequently used PRO measures to assess symptoms are 
the MD Anderson Symptom Inventory Brain Tumor Module (MDASI-BT)49, or the Hospital Anxiety 
and Depression Scale50, while cognitive complaints can be assessed with the MOS Cognitive 
Functioning Scale (MOS CFS)51. Basic activities of daily living are often measured with the Barthel 
Index52, whereas instrumental activities of daily living (i.e. cognitively more complex activities such 
as food preparation) tend to be measured with the Lawton IADL Scale53. HRQoL is frequently 
assessed with the European Organisation of Research and Treatment of Cancer (EORTC) Quality of 
Life Questionnaire (QLQ-C30)54 or the Functional Assessment of Cancer Treatment (FACT)55, both in 
conjunction with their tumour-specific questionnaire56,57. 
9 
 
Although certain measures are often used in brain tumour research, not all are specifically 
developed for and/or validated in brain tumour patients (e.g. the Barthel Index was originally 
developed for patients undergoing rehabilitation after stroke, and the EORTC QLQ-BN20 was only 
validated in glioma patients, not in other types of brain tumour patients). In addition, it is unclear if 
currently used PROs have high content validity, i.e. if the instruments correspond with the construct 
that is intended to be measured, with respect to relevance and comprehensiveness.21 For example, 
the EORTC QLQ-BN20 questionnaire was developed for brain tumour patients in 199614, with a field 
validation in glioma patients in 201056. With the introduction of new treatments, such as targeted 
treatment and immunotherapy, also new toxicities have arisen (e.g. eye and skin problems).40,41 The 
current QLQ-BN20 lacks sufficient coverage of domains that are affected by current and new 
treatment options, as well as issues like behavioural and personality changes, warranting a revision 
of this questionnaire. Moreover, most PROs are static questionnaires consisting of a fixed set of 
items. However, such questionnaires may not meet the current demands of academic researchers 
and industry. When assessing the impact of a new treatment, a fixed set of items may fail to detect 
important (new) adverse events. A more flexible approach, in which a standard set of items could be 
complemented with validated scales, might therefore be a solution.58  
 
RANO-PRO initiative 
The Response Assessment in Neuro-Oncology - Patient Reported Outcome (RANO-PRO) working 
group is an international multidisciplinary collaborative initiative aiming to provide guidance on the 
use of PRO measures in clinical trials and clinical practice for adult brain tumour patients. The 
multidisciplinary working group comprises key physicians and researchers in the field of neuro-
oncology, including liaisons of other RANO working groups, which ensures implementation of 
appropriate PRO measures in future brain tumour research, in accordance with other RANO 
guidelines. Initiatives such as the SPIRIT-PRO, SISAQOL and CONSORT-PRO result in international 
standards for the collection, analysis, interpretation and reporting of PRO data, enhancing the 
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quality of PRO evidence, which are applicable to the whole field of oncology, including neuro-
oncology. However, it is also important to ensure that the PRO instruments are of high quality, both 
in terms of relevance (content validity) for brain tumour patients and other measurement 
properties. In conjunction, these different initiatives may help to improve PRO evidence derived 
from neuro-oncological studies. 
Currently, since no extensive review has been performed, it is not well-known what PRO 
measures have been used in brain tumour research to date, whether these measures exhibit good 
measurement properties, and whether they demonstrate relevance and comprehensiveness for 
brain tumour patients specifically. In addition, more guidance is needed on the selection and 
collection of PROs for each specific study design. Recommendations to enhance several of these 
problems within the field of neuro-oncology have been previously propagated by the Jumpstarting 
Brain Tumor Drug Development Coalition and FDA clinical trials clinical outcome assessment 
endpoints workshop.13 Outcomes from this workshop included identification of priority signs and 
symptoms59, review of COA properties60, and consideration for trial design using COAs61. This work 
could serve as a starting point for further guidelines for use in neuro-oncology. Moreover, from a 
regulatory perspective it is important to include high-quality PROs in neuro-oncological clinical trials 
as they can provide important information for evaluation of benefits and risks of a new treatment, 
and an approach to evaluate or develop appropriate tools is therefore promoted.9  In this paper9, the 
position of the FDA on the use of COAs in clinical trials is outlined, including the demonstration of 
improvement in how patients’ function, feel or survive’, as necessary for product approval. These 
recommendations encourage disease-related function and symptom measures, consideration of the 
impact of therapeutic toxicity, and use of COAs early in the drug development process.  
The goal of the RANO-PRO initiative is to gain insight above mentioned problems, and to 
provide guidance on the use of PRO measures in neuro-oncology. In addition, this initiative will 
result in suggestions for the revision of existing PRO measures and/or development of new PRO 
measures, if appropriate. 
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RANO-PRO working plan 
To achieve the aim proposed by the RANO-PRO working group, a working plan has been set 
up (Figure 2). The first step would be to provide an overview of the guidelines of previous initiatives 
on the collection, analysis, interpretation and reporting of PRO data, which are also applicable to the 
field of neuro-oncology. Gaps should be identified and completed with expert opinion from 
members of the RANO-PRO working  group, taking into account the recommendations that resulted 
from the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials clinical 
outcome assessment endpoints workshop. This may comprise recommendations on the selection 
and collection (including feasibility and patient acceptability) of PROs, particularly with respect to 
the research question and study design. Liaisons from other RANO working groups (e.g. RANO 
epilepsy, RANO NANO, RANO brain metastases and RANO corticosteroids) will be consulted in the 
process, to ensure that their specific needs with respect to the use of PRO will be incorporated.  
A second step would therefore be to identify what PRO measures have been used in brain 
tumour studies so far. As mentioned, several PRO measures are already frequently used (e.g. MDASI-
BT, FACT-Br, EORTC QLQ-C30 and QLQ-BN20, and the Barthel Index), but other instruments may 
exist that are relevant and of methodological high quality. Therefore, a systematic literature review 
will be performed to identify all PRO measures that are used in studies with brain tumour patients, 
following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
guideline (step 2).62 The review will focus on all types of studies (i.e. randomised controlled trials, 
phase I and II trials, natural history studies, symptom management studies, and studies describing 
use of PRO in daily clinical practice) in which a PRO instrument is used to assess symptoms, 
functioning and/or HRQoL in patients with glioma, PCNSL, meningioma or brain metastases.  
  The third step would be to determine the content validity of these existing PRO measures;  
are all important aspects of functioning and health for brain tumour patients covered by these 
instruments? In other words, is a PRO available for each relevant aspect? Also, it would be important 
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to look at the coverage of each PRO instrument. Do the items in a specific PRO cover the domain(s) 
that it intends to measure, such as fatigue (single domain) or HRQoL (multidimensional). This 
information would facilitate the choice for a specific PRO instrument. For this we aim to use the 
framework of the World Health Organisation International Classification of Functioning, Disability 
and Health (WHO ICF) published in 2001.63 This framework refers to functioning at three distinct 
levels. The most basic level is a patient’s impairment, which are problems in body functions, with 
muscle weakness as an example. Assessment of these impairments can be done with PRO measures, 
for instance a symptom questionnaire, but also with ClinRO measures such as a neurological 
examination. Next, the consequences of this impairment in daily life can be observed on a higher 
level, the limitations in a patients’ activity. This would mean that the patient with muscle weakness 
is not able to walk around or drive a car. PRO instruments assessing (instrumental) activities of daily 
living can be used to measure these activity limitations. The highest level of functioning, the so-
called participation restrictions, reflects the way the dysfunction affects the patient’s well-being and 
social interaction. In line with our example, this would mean that the patient with muscle weakness 
who is unable to walk or drive a car, may be less likely to visit friends or family. HRQoL measures 
usually include domains reflecting these participation restrictions. Nevertheless, since this ICF 
classification system is very extensive, it would be important to determine the aspects of functioning 
that are most relevant for (each type of) brain tumour patients. To detect these most important 
aspects, we aim to conduct an international survey amongst brain tumour patients, their informal 
caregivers, and experts in the field of neuro-oncology. This would allow to further refine the list of 
most relevant disease-related symptoms for assessment in clinical trials on a global level, as 
measured in the online survey of the Jumpstarting Brain Tumor Drug Development Coalition 
conducted in the United States.13  Based on these results, we will be able to evaluate if current PRO 
instruments cover all aspects that are relevant to brain tumour patients. For relevant aspects not 
covered in existing PRO measures, we might consider revision of certain instruments or 
development of new PRO measures. 
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A fourth step would be to determine the psychometric properties of these identified PRO 
measures. How valid and reliable are these instruments for the use in brain tumour patients? To 
judge the methodological quality of studies on the measurement properties of PRO instruments, the 
COSMIN criteria will be applied. The COSMIN taxonomy distinguishes three quality domains, i.e. 
reliability, validity, and responsiveness, each including one or more measurement properties.21 
Reliability refers to the degree to which the measurement is without measurement error, while 
validity refers to the degree to which an instrument truly measures the construct it intends to 
measure. Responsiveness refers to the ability of an instrument to detect (clinically relevant) changes 
over time.21 PRO measures that do not meet the standard as set by the COSMIN might still be 
important and relevant. For example, a measure that has not yet been validated in brain tumour 
patients, and as such does not meet the requirements for satisfactory measurement properties, 
might be evaluated in a field validation study to meet these standards. 
 
Conclusion 
The objective of the RANO-PRO initiative is to provide guidance on the use of PRO measures in 
clinical studies and clinical practice of adult brain tumour patients. In conjunction with guidelines on 
the collection, analysis, interpretation and reporting of PRO data, this guidance may help to improve 
the PRO evidence derived from neuro-oncological studies, which may subsequently be used to 
inform the research community, policy makers, and physicians and patients in treatment decision-
making. 
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Table 1. Definition of Clinical Outcome Assessment (COA), and each subtype  
Clinical Outcome Assessment (COA) Any assessment that may be influenced by human choices, 
judgment, or motivation and may support either direct or 
indirect evidence of treatment benefit. Unlike biomarkers that 
rely completely on an automated process or algorithm, COAs 
depend on the implementation, interpretation, and reporting 
from a patient, a clinician, or an observer. 
Patient-reported outcome (PRO) A measurement based on a report that comes from the patient 
(i.e., study subject) about the status of a patient’s health 
condition without amendment or interpretation of the 
patient’s report by a clinician or anyone else. A PRO can be 
measured by self-report or by interview, provided that the 
interviewer records only the patient’s response. Symptoms or 
other unobservable concepts known only to the patient (e.g., 
pain severity or nausea) can only be measured by PRO 
measures. PROs can also assess the patient perspective on 
functioning or activities that may also be observable by others. 
Clinician-reported outcome (ClinRO) Is based on a report that comes from a trained health-care 
professional after observation of a patient’s health condition. 
A ClinRO measure involves a clinical judgment or 
interpretation of the observable signs, behaviours, or other 
physical manifestations thought to be related to a disease or 
condition. ClinRO measures cannot directly assess symptoms 
that are known only to the patient (e.g., pain intensity). 
Observer-reported outcome (ObsRO) A measurement based on an observation by someone other 
than the patient or a health professional. This may be a 
parent, spouse, or other non-clinical caregiver who is in a 
position to regularly observe and report on a specific aspect of 
the patient’s health. An ObsRO measure does not include 
medical judgment or interpretation. Generally, ObsROs are 
reported by a parent, caregiver, or someone who observes the 
patient in daily life. For patients who cannot respond for 
themselves (e.g., infants or cognitively impaired), we 
encourage observer reports that include only those events or 
behaviours that can be observed. As an example, observers 
cannot validly report an infant’s pain intensity (a symptom) 
but can report infant behaviour thought to be caused by pain 
(e.g., crying). For example, in the assessment of a child’s 
functioning in the classroom, the teacher is the most 
appropriate observer. Examples of ObsROs include a parent 
report of a child’s vomiting episodes or a report of wincing 
thought to be the result of pain in patients who are unable to 
report for themselves.  
Performance outcome (PerfO) A measurement based on a task(s) performed by a patient 
according to instructions that is administered by a health care 
professional. Performance outcomes require patient 
cooperation and motivation. These include measures of gait 
speed (e.g., timed 25 foot walk test), memory recall, or other 
cognitive testing (e.g., digit symbol substitution test). 
* Source: Food and Drug Administration (FDA), Clinical Outcome Assessment Qualification Program 
Table 2. Current efforts to standardise practice for use of patient-reported outcomes in oncology 
Initiative Aim 
Recommendation for Interventional 
Trials in Patient-Reported Outcomes 
(SPIRIT-PRO) 
To provide guidance on what specific PRO protocol items 
should be included in trial protocols 
Setting International Standards in 
Analyzing Patient-Reported Outcomes 
and Quality of Life Endpoints (SISAQOL) 
To develop a guideline and best practices fore 
standardising the analysis and interpretation of PRO 
outcomes in cancer clinical trials 
International Society for Quality of Life 
Research (ISOQOL); CONsolidated 
Standards of Reporting Trials in Patient 
Reported Outcomes (CONSORT-PRO) 
To standardise the level of PRO reporting 
COnsensus-based Standards for the 
selection of health Measurement 
Instruments (COSMIN) 
To develop standards for the evaluation of the 
methodological quality of studies on the measurement 
properties of health measurement instruments, including 
PRO measures 
Food and Drug Administration 
Guidance for Industry Patient-Reported 
Outcome Measures: Use in Medical 
Product Development to Support 
Labelling Claims 
To provide guidance on the optimal PRO development, 
trial design and analysis of PRO data, which can be 
specifically used to support oncology labelling claims  
 
